Drug Combo Lowers Heart Risks for Breast Cancer Patients

Friday, 07 October 2011 09:24 AM

A new study published in the New England Journal of Medicine found the risk of heart damage from Herceptin, a breast-cancer drug, almost can be eliminated if it is combined with a different chemotherapy medicine.
Herceptin generally is administered with the adriamycin, a well-known chemotherapy drug that can elevate the risk of heart problems. The study said if Herceptin is combined with carboplatin, the heart risk drops “five fold.”
Dr. Dennis Slamon, of the University of California at Los Angeles, co-discovered Herceptin years ago and started combining it with carboplatin, frequently used in patients with ovarian cancer.
There is one drawback, the New England Journal of Medicine said. When Herceptin was combined with carboplatin in the study, there were more recurrences of breast cancer, although they were “not statistically significant,” the study found.
More than 3,200 women were monitored by researchers for five years.

© HealthDay

1Like our page
Friday, 07 October 2011 09:24 AM
Newsmax Media, Inc.

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved